Neutral HMOs Modulate Gut-Brain Axis for Mood Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anxiety and depression, such as antidepressant medications, have suboptimal response rates and significant side effects, and there is a need for a safer and more effective approach, particularly for patients with stress, bacterial overgrowth, dysbiosis, and impaired mucosal barriers.
Innovation Solution
The use of neutral human milk oligosaccharides (HMOs), specifically 2′-FL, 3-FL, LNT, LNnT, and LNFP-I, in a synthetic composition to promote beneficial bacteria growth, reduce bacterial overgrowth and dysbiosis, and repair the mucosal barrier, potentially influencing neurotransmission and reducing anxiety and depression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antidepressant medications are used to treat anxiety and depression, then mood symptoms can be managed, but side effects increase and response rates remain suboptimal
Solution Approach 1:
The patent introduces neutral HMOs as an intermediary substance that indirectly influences neurotransmission through gut-brain axis modulation rather than directly acting on the central nervous system. This mediates the treatment effect through beneficial bacteria metabolism, reducing direct pharmacological side effects while maintaining therapeutic efficacy for mood disorders
Solution Approach 2:
The patent replaces the conventional direct pharmacological mechanism (chemical drugs acting on brain receptors) with a biological mechanism (prebiotics modulating gut bacteria which then produce neuroactive metabolites). This substitution of the action mechanism eliminates many side effects associated with direct antidepressant medication while maintaining treatment effectiveness
2Adaptability or versatility
If conventional antidepressants are administered, then some symptom relief may be achieved, but individual response varies significantly and many patients do not respond adequately
Solution Approach 1:
The patent enables the patient's own gut microbiota to produce the therapeutic effect through metabolism of neutral HMOs into neuroactive compounds like GABA and short-chain fatty acids. This self-service mechanism adapts to each individual's unique microbiome composition, naturally providing personalized treatment response without requiring dose adjustments or switching medications
Solution Approach 2:
The patent changes the fundamental treatment parameter from direct central nervous system pharmacology to gut microbiome modulation. By targeting the gut-brain axis and allowing individual microbiome variations to determine the specific metabolite profile, the treatment adapts to each patient's biological parameters, reducing response variability and improving adequate treatment response rates
3Reliability
If the gut-brain axis is modulated through neutral HMOs, then neurotransmission may be influenced and mood improved, but the mechanism is complex involving multiple bacterial metabolites
Solution Approach 1:
The patent extracts and isolates the specific beneficial action from the complex gut-brain axis system by focusing on neutral HMOs as the key prebiotic substrate. By identifying and administering these specific oligosaccharides that consistently produce beneficial metabolites (GABA, short-chain fatty acids), the complex natural system is simplified into a targeted therapeutic intervention with predictable outcomes
Solution Approach 2:
The patent demonstrates that neutral HMOs serve multiple functions simultaneously: they act as prebiotics to promote beneficial bacteria growth, serve as substrates for producing neuroactive metabolites, reduce inflammation, and strengthen the mucosal barrier. This multi-functionality consolidates multiple therapeutic actions into a single treatment agent, simplifying the overall treatment approach despite the complex underlying mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Neutral HMOs effectively treat anxiety and depression by promoting bifidobacteria growth, reducing inflammation, and repairing the mucosal barrier, leading to improved mood and emotional responses, as demonstrated in clinical trials with reduced symptoms and increased bifidobacteria abundance.
Implementation Method 1
Neutral HMOs for use as prebiotics to promote beneficial bacteria growth
Implementation Method 2
bacteria growth, reduce bacterial overgrowth and dysbiosis, and repair the mucosal barrier, potentially influencing neurotransmission
Data Source
AI summary
A synthetic composition for use in treating or improving one or more emotion and/or mood disorders in a patient, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.